3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
34
Neoplasm Metastasis
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Adenocarcinoma
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Radiation Injuries
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligometastatic Prostate Cancer
1
Neoplasm Recurrence, Local
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Gastrointestinal Diseases
1
Erectile Dysfunction
1
Breast Neoplasms
1
Interventions
testosterone 17 beta-cypionate
1
pembrolizumab
1
enfortumab vedotin
1
Testosterone Propionate
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Mitomycin
1
Methyltestosterone
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Diseases
×
Androgen Antagonists
×
90 days
×
Clear all
NCT07483658
2026-03-19
HYP-OP-RT
CHU de Quebec-Universite Laval
Phase NA
Not yet recruiting
434 enrolled